DNX-2401 oncolytic adenovirus phase 1 trial results

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma (click here for abstract)

I've uploaded the full PDF to the Brain Tumor Library -> 1. Therapies - human studies -> DNX-2401

In group A, 5 out of 25 patients (20%) lived for at least 3 years post-injection of DNX-2401, and three of these (12%) had dramatic responses (at least 95% reduction in cross-sectional area of enhancing tumor) and at least three years of progression-free survival.

This therapy is currently being tested in combination with pembrolizumab (anti-PD-1).

https://clinicaltrials.gov/ct2/show/NCT02798406

DNX-201 With Pembrolizumab (Keytruda)

Hello All,

I am looking for any comments, experience and suggestions with the DNX-2401 trial.

The Phase II just opened and I am enrolled for the procedure on Monday.

My GBM was resected in June 2015 and there has been some mass increases in the area between my cavity and skull.  Shows some signs of tumor and some signs as necrosis.


Of the couple of trial options offered to me, (southern California) these seems like the best, like the biopsy aspect of this trial.

When I asked a GBM research scientist friend of mine, I got the following comment:

Paraphased:

 - DNX-2401 is a one shot try.  If it comes back up the biopsy hole, then nothing is going to happen.

So this makes sense, that if no DNX-201 then nothing for the PD1 to work on.

But is this really a concern?

Any, why cannot you just re-inject if this happens?

Marc

TG6002 oncolytic and vectorized virus, clinical trial for recurrent GBM in France

This upcoming trial in France is comparable to the Toca511/TocaFC trials in the US, in that it uses a viral vector to transmit a "suicide gene" to tumor cells that cause them to convert 5-fluorocytosine into the chemotherapy drug 5-fluorouracil.  The virus used in this trial, TG6002, is also oncolytic, meaning that it can kill tumor cells, even without the suicide gene + prodrug component.

https://clinicaltrials.gov/ct2/show/NCT03294486

More information on the lab studies with this therapy can be found here.

Immunotheraphy combo

Do you have any experience or thoughts about this study?
http://www.practiceupdate.com/c/57122/67/12/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_braincancer&elsca4=braincancer&elsca5=newsletter&rid=MjMxMDE2NzMzNjcyS0&lid=10332481

Has anyone tried this combo?
Best wishes to all
Brainbutton

Updated statistics from Duke's modified poliovirus trial for recurrent GBM

• As of 2/01/2017, 52 pts were treated on study (1 each at DL1 and DL3, 7 at DL2, 2 at DL4, 4 at DL5, 24 at DL-1 and 13 at DL-2)

• 20.8% of pts remain alive at 36-month post PVSRIPO infusion, compared to 4% of an historical control.

• Four pts remain alive more than 22 months post treatment without having received any additional intervention following PVSRIPO at 57.5+, 56.4+, 27.9+ and 23.2+ months.

An important thing to keep in mind is that the patients in this phase 1 trial were treated with various doses of the virus.  We can expect future trials that move forward with the approximately optimal dose to have better overall results than this trial.  The first patient in this trial is now 5 years in remission.

http://abstracts.asco.org/199/AbstView_199_192524.html

Upcoming trial of modified poliovirus for children ages 12-18 with recurrent malignant glioma

The anticipated start date is June of this year.

Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children
NCT03043391

Brain Research Institute

I found this link on ABTA and thought it was helpful. 

http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/brain-cancer